Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

Inclusion criteria

• Provision of written informed consent, or assent with parental or guardian written consent*
• Known O. volvulus skin microfilariae density ≥0 microfilariae/mg skin (participants ≥12 years of age only).
• Living in an onchocerciasis endemic area.
• Age ≥4 years
• All female participants of childbearing potential must commit to the use of a reliable method of birth control until 3 months after administration of investigational product (Month 3). * Expression of 'deliberate objection' will be the basis for assessing assent of children aged ≥ 4 to <6 years

Exclusion criteria

• Pregnant or breast-feeding.
• Any concurrent condition that, in the opinion of the Investigator, would preclude evaluation of response to treatment or would pose undue risk to the participant's health.
• Has received ivermectin or oral diethylcarbamazine (DEC) within 30 days of Baseline.
• Has received treatment with an investigational agent within the 30 days (or 5 half-lives, whichever is longer) prior to planned investigational product administration.
• Known or suspected allergy to ivermectin or moxidectin or their excipients and, in areas with high levels of LF co-endemicity, known or suspected allergy to albendazole and its excipients.
• Self-reported planned or ongoing activities within the study period that would make it unlikely that the participant will be available for follow-up examinations.
• Infection with Loa loa.
• Height <90 cm.